InnoCan Pharma Corporation
INNO
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 29.44M | 28.93M | 24.39M | 18.87M | 13.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.44M | 28.93M | 24.39M | 18.87M | 13.66M |
| Cost of Revenue | 3.25M | 2.86M | 2.44M | 2.26M | 1.68M |
| Gross Profit | 26.19M | 26.07M | 21.95M | 16.61M | 11.98M |
| SG&A Expenses | 25.89M | 25.56M | 22.95M | 18.74M | 13.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.68M | 30.15M | 27.17M | 22.61M | 17.46M |
| Operating Income | -1.25M | -1.22M | -2.78M | -3.75M | -3.80M |
| Income Before Tax | 919.00K | 334.00K | -2.20M | -4.03M | -4.03M |
| Income Tax Expenses | 1.18M | 1.34M | 926.00K | 448.00K | 214.00K |
| Earnings from Continuing Operations | -0.26 | -1.01 | -3.12 | -4.47 | -4.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.57M | -1.59M | -1.22M | -724.00K | -453.00K |
| Net Income | -1.83M | -2.60M | -4.34M | -5.20M | -4.70M |
| EBIT | -1.25M | -1.22M | -2.78M | -3.75M | -3.80M |
| EBITDA | -1.21M | -1.19M | -2.74M | -3.71M | -3.77M |
| EPS Basic | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.12B | 1.10B | 1.08B | 1.05B | 1.03B |
| Average Diluted Shares Outstanding | 1.12B | 1.10B | 1.08B | 1.05B | 1.03B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |